Efficacy and safety of darolutamide versus abiraterone acetate plus prednisone in combination with ADT for mHSPC: a real-world clinical retrospective study

Efficacy and safety of darolutamide versus abiraterone acetate plus prednisone in combination with ADT for mHSPC: a real-world clinical retrospective study

IntroductionEffective treatment during the metastatic hormone-sensitive prostate cancer (mHSPC) stage is crucial for delaying disease progression. Due to the lack of a head-to-head comparison of darolutamide (DARO) and abiraterone acetate plus prednisone (AAP) doublet regimen, this study aims to com...

Full description

Saved in:
Bibliographic Details
Main Authors: Ting Hu, Fang Zhou, Yang Zheng, Bohan Luo, Yongliang Zhang, Chengpeng Gu, Guopeng Wang, Jinze Zhang, Jingzhi Tian, Yu Nie, Yunlin Feng, Shangqing Ren, Wenjia Di, Dong Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Pharmacology
Subjects:
metastatic hormone-sensitive prostate cancer
darolutamide
abiraterone acetate
androgen deprivation therapy
efficacy
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1608339/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1608339/full

Similar Items